Culture’s biomanufacturing platform empowers customers todesign and manage high-throughput fermentation experiments from the cloud.

SouthSan Francisco, CA, February 12, 2019--CultureBiosciences, the South San Francisco-based biotech company pioneeringbiomanufacturing-as-a-service, today announced $5.5 million in funding led bySection 32, with participation from Refactor Capital and Verily. Culture willuse the funding to expand its digital biomanufacturing platform and developadditional bioreactor facilities.

“Biotechnology is poised to transformindustries ranging from healthcare to food, but it is limited by arduous andtime consuming approaches to fermentation, the key process involved inmanufacturing bio-based products at scale,” said Culture Biosciences CEO WillPatrick. “Our goal is to make fermentation a digital experience, empoweringscientists to run experiments from their computers in the same way a softwareengineer tests and compiles code. We’re proud to have the support of suchcommitted investors as we pursue our vision of supporting companies as theybuild breakthrough products.”

Across industrial, pharmaceutical andagricultural biotechnology, companies often struggle to scale their lab-basedprojects into commercial solutions. This scale-up process is bottlenecked bylegacy approaches to fermentation, which require companies to either buildin-house fermentation facilities or contract an outside lab to run theirexperiments. Both approaches are limited in speed, flexibility and convenience,contributing to lengthy lab-to-market timelines that can stretch well beyondfive years and cost companies hundreds of millions of dollars in R&Dexpenses.

Culture is developing a digitalbiomanufacturing platform to enable companies to run, monitor and analyzebioreactor experiments for faster and more convenient biotech productdevelopment. Culture’s platform, which integrates best-in-class bioreactors,cloud monitoring capabilities and remote operations, is currently being used byleading biotechnology companies to optimize their R&D processes.

Customers who join the Culture network haveaccess to custom built and engineered bioreactors equipped with novel roboticsystems for more efficient operation, cloud monitoring capabilities to gainreal-time insights, fast data transfer and sample shipping, and same-dayprocess design changes. Customers can access the Culture system through anycloud-connected device, and can remotely manage their experiment as if theywere running it themselves.

“We are excited to lead this investment inCulture Biosciences, which is empowering companies to focus on what they dobest – creating groundbreaking technology and turning it into great products,”said Dr. Mike Pellini, Managing Partner at Section 32.

AboutCulture Biosciences

Culture Biosciences is a biotechnology company based in South San Francisco, CA, that’s building the future of biomanufacturing. Culture’s digital biomanufacturing platform enables companies to run, monitor and analyze bioreactor experiments from the cloud. Culture is proud to count Section 32, Refactor Capital and Verily among its investors, and is a resident of the Verily Partner Space. To learn more, please visit www.culturebiosciences.com.

Source: https://www.prnewswire.com/news-releases/culture-biosciences-secures-5-5m-to-pioneer-biomanufacturing-as-a-service-300793521.html